An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Avivagen to Hold Webcast to Discuss Landmark Deal with AB Vista
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Avivagen Inc. has established an exclusive distribution partnership with AB Vista for its OxC-beta™ product across the United States, Brazil, and Thailand, targeting poultry, swine, ruminants, and aquaculture sectors. The company will hold a webcast on October 6, 2021, at 10:30 a.m. EDT to discuss this agreement. OxC-beta™ technology is a non-antibiotic alternative that supports immune function and promotes livestock health. The product has shown efficacy comparable to traditional in-feed antibiotics in international trials.
Positive
Exclusive distribution agreement with AB Vista for OxC-beta™ product.
Expansion into significant markets: US, Brazil, and Thailand.
OxC-beta™ technology offers a non-antibiotic alternative to promote livestock health.
Negative
None.
-AB Vista becomes the exclusive distribution partner for OxC-beta™ for poultry, swine, ruminants (dairy and beef) and aquaculture uses in the United States, Brazil and Thailand
-Webcast to take place Wednesday, October 6th, 2021, at 10:30 a.m. EDT
OTTAWA, Ontario--(BUSINESS WIRE)--
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce it will be holding a webcast on Wednesday, October 6th at 10:30 A.M. EDT to discuss its recent sales agreement with AB Vista that was announced on Friday, October 1, 2021.
The webcast will commence with remarks by Avivagen CEO Kym Anthony, followed by a Q & A session. To access the live webcast, visit this link to the event(http://public.viavid.com/index.php?id=146815). Please pre-register questions with Investor Relations ahead of time. Following the live webcast, an archived version of the call will be available on Avivagen’s website.
About Avivagen
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.
About OxC-beta™ Technology and OxC-beta™ Livestock
Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia, and Malaysia.
Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.
Avivagen Inc. Drew Basek Director of Investor Relations
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Phone: 416-540-0733
E-mail: d.basek@avivagen.com
Kym Anthony Chief Executive Officer
100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6 Head Office Phone: 613-949-8164
Website: www.avivagen.com
Source: Avivagen Inc.
FAQ
What is the significance of Avivagen's partnership with AB Vista?
Avivagen's exclusive distribution partnership with AB Vista is significant as it expands the market reach of its OxC-beta™ product in the US, Brazil, and Thailand, targeting major livestock sectors.
When will Avivagen's webcast discussing the AB Vista agreement take place?
The webcast will take place on October 6, 2021, at 10:30 a.m. EDT.
What benefits does OxC-beta™ provide for livestock?
OxC-beta™ provides a non-antibiotic solution that supports immune function and promotes overall health in livestock, serving as an effective alternative to traditional in-feed antibiotics.
What markets will Avivagen's OxC-beta™ product be distributed in?
The OxC-beta™ product will be distributed in the United States, Brazil, and Thailand.
